Ascend – Recall of dabigatran etexilate capsules
March 22, 2023 - Ascend Laboratories announced a consumer-level recall of dabigatran etexilate capsules, 75 mg and 150 mg, due to the presence of a nitrosamine, N-nitroso-dabigatran, above the established FDA acceptable daily intake level.
Download PDF
